Every Form 4 that Cross Country Healthcare Inc (CCRN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CCRN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CCRN filings page.
Cross Country Healthcare, Inc. reported that Chief Accounting Officer Marvin Veizaga’s equity was settled in cash in connection with a merger in which the company became a wholly owned subsidiary of KL Criss Cross Intermediate, LLC. On 2026-07-21 he disposed of 31480 shares of common stock to the issuer at $13.25 per share, while performance-based restricted stock awards covering 16797 shares first vested at target and were then cancelled for the same cash merger consideration.
Cross Country Healthcare Chief Operating Officer Amiee Lin Hawkins reported equity changes tied to a cash merger. At the merger’s effective time, 43,953 common shares and 27,897 performance-based restricted stock awards were disposed of to the issuer and converted into the right to receive $13.25 in cash per share.
Cross Country Healthcare executive Marc S. Krug reported share-based transactions tied to a merger in which each share of common stock was converted into the right to receive $13.25 in cash. Outstanding restricted and performance-based stock awards vested, were cancelled, and converted into equivalent cash rights at that merger consideration.
Susan E. Ball, General Counsel and Secretary of Cross Country Healthcare, reported Form 4 transactions tied to the closing of a merger in which the company became a wholly owned subsidiary of KL Criss Cross Intermediate. At the merger’s Effective Time, each share of common stock converted into the right to receive $13.25 in cash.
In connection with this, she reported issuer dispositions of 241,777 and 72,872 shares of common stock at $13.25 per share, reflecting conversion of common and restricted stock into cash consideration. She also reported the vesting, at target, of a 72,872‑share performance-based restricted stock award, which was then cancelled and cashed out at the merger price.
Cross Country Healthcare Inc. Chief Financial Officer William J. Burns reported equity changes in connection with a merger in which the company became a wholly owned subsidiary of KL Criss Cross Intermediate, LLC. At the merger’s Effective Time, 336,438 common shares and 104,157 shares underlying performance-based restricted stock awards were disposed to the issuer, each automatically converted into the right to receive $13.25 in cash per share. The 104,157 performance-based awards first vested at target levels and were recorded as an acquisition at no cost before being cancelled for the same cash consideration.
Cross Country Healthcare Chief Executive Officer Clark Kevin Cronin reported merger-related equity transactions on July 21, 2026. In connection with the company’s acquisition by KL Criss Cross Intermediate, his common and restricted shares, including performance-based awards and shares held by his spouse, were converted and disposed to the issuer for $13.25 per share in cash merger consideration.
Cross Country Healthcare Inc director Janice Elizabeth Nevin reported a disposition of 48,616 shares of common stock on 2026-07-21. These shares were automatically converted into the right to receive $13.25 in cash per share at the effective time of a merger, leaving her with no reported holdings of this stock.
Cross Country Healthcare director Gale S. Fitzgerald reported dispositions of common stock to the issuer in connection with a merger in which each share was converted into the right to receive $13.25 in cash. She disposed of 114,331 directly held shares, while a family trust disposed of 79,918 shares; Fitzgerald disclaims beneficial ownership of the trust-held shares, and no common stock holdings remain reported.
CROSS COUNTRY HEALTHCARE INC director Larry W. Cash reported a disposition of 223,312 shares of Common Stock on July 21, 2026. The shares were surrendered to the issuer in connection with a merger in which each share was automatically converted into the right to receive $13.25 in cash. Following this transaction, Cash reported owning 0 shares of Cross Country common stock. Restricted stock awards were also fully vested, cancelled and converted into cash based on the same $13.25 per-share merger consideration.
CROSS COUNTRY HEALTHCARE INC director Venkat Bhamidipati disposed of 29,759 shares of common stock on July 21, 2026 in connection with a merger. The shares were converted into the right to receive $13.25 in cash per share under a merger agreement with KL Criss Cross Intermediate, LLC and its subsidiary, leaving him with no remaining shares of the issuer.
Dwayne Allen, a director of Cross Country Healthcare, reported a disposition to the issuer of 31,289 shares of common stock at $13.25 per share. The transaction occurred at the Effective Time of a merger in which Cross Country Healthcare became a wholly owned subsidiary of KL Criss Cross Intermediate, LLC, and left Allen with 0 shares of common stock. Under the merger terms, each outstanding share and restricted stock award was automatically converted into the right to receive cash based on the same $13.25 per-share Merger Consideration.
CROSS COUNTRY HEALTHCARE INC Chief Accounting Officer Marvin Veizaga reported a Form 4 transaction involving company common stock. On July 9, 2026, 236 shares were disposed of through share withholding to satisfy tax obligations arising from restricted stock vesting, rather than an open-market sale. Following this tax-withholding disposition, Veizaga holds 31,480 shares of common stock directly.
CROSS COUNTRY HEALTHCARE INC Group President, Delivery Marc S. Krug reported equity compensation activity involving the company’s common stock. He received a grant of 21,024 restricted shares that vest in three substantially equal installments on March 31, 2027, March 31, 2028 and March 31, 2029.
On the same date, 1,123 shares and 1,339 shares were withheld at a price of $9.40 per share to cover tax withholding obligations for restricted stock that vested on March 31, 2026. After these transactions, Krug directly owns 77,232 common shares.
CROSS COUNTRY HEALTHCARE INC Chief Operating Officer Amiee Lin Hawkins reported routine equity compensation and related tax withholding in company stock. She received a grant of 15,958 restricted shares of common stock, which vest in three substantially equal installments on March 31, 2027, March 31, 2028 and March 31, 2029. To cover tax obligations on restricted stock that vested on March 31, 2026, a total of 1,278 shares were withheld at a price of $9.40 per share through two transactions. After these transactions, she directly holds 43,953 shares of common stock.
Clark Kevin Cronin reported acquisition or exercise transactions in this Form 4 filing.
Cross Country Healthcare Chief Executive Officer Kevin Cronin reported an award of 138,963 shares of restricted common stock at no purchase price. These shares vest in three substantially equal installments on March 31, 2027, March 31, 2028 and March 31, 2029.
Following the award, he holds 948,133 shares directly. A separate line reflects 3,961 shares held indirectly by his spouse, for which he disclaims beneficial ownership except for any pecuniary interest.
CROSS COUNTRY HEALTHCARE INC Chief Financial Officer William J. Burns reported routine equity compensation and related tax withholding transactions in company stock. He received a grant of 47,873 restricted shares of common stock at no cost, which vest in three substantially equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.
To cover tax obligations on restricted stock that vested on March 31, 2026, 2,423 shares and 2,890 shares of common stock were withheld at a value of $9.40 per share. After these transactions, Burns directly holds 336,438 shares of CROSS COUNTRY HEALTHCARE INC common stock.
Cross Country Healthcare General Counsel Susan E. Ball reported routine equity compensation and related tax withholding transactions. On March 31, 2026, she received a grant of 33,644 shares of common stock at no cost, described as restricted shares that will vest in three substantially equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.
On the same date, 1,689 and 2,014 shares were withheld at $9.40 per share to satisfy tax withholding obligations for restricted stock that vested on March 31, 2026. After these transactions, she directly holds 241,777 shares of Cross Country Healthcare common stock.
CROSS COUNTRY HEALTHCARE INC Chief Accounting Officer Marvin Veizaga reported equity compensation activity in company stock. He received a grant of 9,043 shares of common stock, described as restricted shares that vest in three substantially equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. To cover tax withholding obligations for restricted stock that vested on March 31, 2026, 938 shares were withheld in two transactions at $9.40 per share. After these transactions and a correction for 4,471 previously omitted shares from an earlier Form 3, Veizaga directly holds 31,716 shares of common stock.
CROSS COUNTRY HEALTHCARE INC Chief Human Resources Officer Colin Patrick McDonald sold 6,200 shares of common stock in an open-market transaction on March 11, 2026 at a weighted average price of about $9.70 per share. After this sale, he directly holds 28,060 shares of the company’s common stock.
Cross Country Healthcare’s General Counsel and Secretary, Susan E. Ball, reported an amended insider transaction reflecting tax withholding tied to restricted stock vesting. On March 31, 2025, multiple entries show shares of common stock withheld to cover tax obligations, including transactions of 1,740, 1,689, 2,015 and 3,942 shares at a price of $14.89 per share. These were coded as “F,” indicating shares withheld by the issuer rather than open-market sales. After these transactions, she directly beneficially owned 176,032 shares of Cross Country Healthcare common stock. The amendment corrects the transaction date originally reported as April 2, 2025, confirming that the activity occurred on March 31, 2025.
Cross Country Healthcare Inc. reported that its Chief Accounting Officer received a grant of 12,311 restricted shares of common stock on December 18, 2025. These shares were granted at a price of $0 and increase the officer’s directly owned common stock to 31,110 shares after the transaction.
The restricted stock award will vest in three substantially equal installments on December 18, 2026, March 31, 2027, and March 31, 2028. The Compensation Committee approved the number of restricted shares to be granted on December 18, 2025, following the termination of a Merger Agreement with Aya Holdings II Inc., Spark Merger Sub One Inc. and Aya Healthcare, Inc. on December 3, 2025. After the first vesting date 12 months from grant, the remaining installments will vest on March 31 of the next two years to align with prior awards.
Cross Country Healthcare, Inc. reported that director Kevin C. Clark received a grant of 162,672 restricted shares of common stock on December 18, 2025 at a price of $0. These restricted stock awards vest in three substantially equal installments on December 18, 2026, March 31, 2027, and March 31, 2028, with later vesting dates aligned to the company’s existing restricted stock schedule.
The grant amount was approved on December 18, 2025 following the termination of a Merger Agreement with Aya Holdings II Inc., Spark Merger Sub One Inc. and Aya Healthcare, Inc. on December 3, 2025. After this award, Mr. Clark beneficially owns 809,170 shares directly and 3,961 shares indirectly through his spouse, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
Cross Country Healthcare, Inc. reported that its General Counsel and Secretary, Susan E. Ball, received a grant of 35,804 restricted shares of common stock on December 18, 2025 at a stated price of $0. Following this grant, she beneficially owns 211,836 shares directly.
The restricted shares vest in three substantially equal installments on December 18, 2026, March 31, 2027 and March 31, 2028. The Compensation Committee approved the number of restricted shares to be granted on December 18, 2025 instead of March 31, 2025, after the termination of the Merger Agreement with Aya Holdings II Inc., Spark Merger Sub One Inc. and Aya Healthcare, Inc. on December 3, 2025.